info@PremierEndpoint.com (914) 315-9334

SAN DIEGO, Oct. 5, 2017 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved an 80 mg INGREZZA® (valbenazine) capsule strength to be used for the treatment of adults with tardive dyskinesia (TD). INGREZZA, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, which was approved by […]

Ablynx scores with blood clot drug
October 2, 2017

Belgian biotech company Ablynx has received a boost with strong results from a late-stage trial into its experimental drug caplacizumab to treat a rare, life-threatening autoimmune blood clotting disorder. Acquired thrombotic thrombocytopenic purpura (aTTP) is caused by impaired activity of the ADAMTS13 enzyme and results in very low platelet count plus clot formation in small […]

Yet another once-promising treatment for Alzheimer’s disease has come up short in the final stage of development, this time adding Wall Street drama to the familiar disappointment that has plagued the drug industry for decades. A pill called intepirdine, developed by the biotech startup Axovant Sciences, failed to blunt the symptoms of Alzheimer’s in a […]

FDA rejects Janssen’s Plivensia
September 25, 2017

Johnson & Johnson has been left “disappointed” after the FDA rejected its rheumatoid arthritis drug Plivensia (sirukumab). Efficacy is not the issue – but in a complete response letter to Janssen Biotech, the US regulator said that it needs additional clinical data to further evaluate its safety in the treatment of moderately to severely active […]

3 Ways AI Is Changing Medicine
September 21, 2017

Recent developments in artificial intelligence (AI) are turning science fiction into science fact — and deep learning is at the heart of these advances. These AI systems have the ability to sift through scores of data, recognize patterns, and detect differences that might be imperceptible to humans. Some applications are already achieving remarkable results. One […]

LISBON, PORTUGAL—Novo Nordisk’s combination med Xultophy, which marries its GLP-1 blockbuster Victoza and newest basal insulin Tresiba, became the latest diabetes med to show it could dampen risk factors for cardiovascular disease. The analysis, unveiled Wednesday at the European Association for the Study of Diabetes meeting in Lisbon, showed Xultophy patients had significantly lower systolic […]

1 2 3 17